公开(公告)号：US11572364B2

公开(公告)日：2023-02-07

申请号：US17188132

申请日：2021-03-01

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： David Lauffer ,  Guy Bemis ,  Michael Boyd ,  David Deininger ,  Hongbo Deng ,  Warren Dorsch ,  Wenxin Gu ,  Russell R. Hoover ,  Mac Arthur Johnson, Jr. ,  Mark Willem Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Marina Penney ,  Darin Takemoto ,  Nathan D. Waal ,  Tiansheng Wang ,  Pan Li

IPC: C07D471/04 ,  C07D487/04 ,  C07D491/20 ,  C07D487/14 ,  C07D519/00 ,  C07D471/14 ,  C07D498/04

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US11440907B1

公开(公告)日：2022-09-13

申请号：US17004109

申请日：2020-08-27

Applicant: Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

Inventor： Henry Yu ,  Michael Clark ,  Guy Bemis ,  Michael Boyd ,  Kishan Chandupatla ,  Philip Collier ,  Hongbo Deng ,  Huijun Dong ,  Warren Dorsch ,  Russell R. Hoover ,  Mac Arthur Johnson, Jr. ,  Shashank Kukarni ,  Marina Penney ,  Steven Ronkin ,  Darin Takemoto ,  Qing Tang ,  Nathan D. Waal ,  Tiansheng Wang ,  David J. Lauffer ,  Pan Li

IPC: A61K31/506 ,  A61K31/553 ,  A61P35/00 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D491/107 ,  C07D417/14 ,  C07D403/04 ,  C07D491/113

Abstract: The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US10391095B2

公开(公告)日：2019-08-27

申请号：US16042206

申请日：2018-07-23

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Kevin Michael Cottrell ,  Hongbo Deng ,  John P. Duffy ,  Huai Gao ,  Simon Giroux ,  Jeremy Green ,  Katrina Lee Jackson ,  Joseph M. Kennedy ,  David J. Lauffer ,  Mark Willem Ledeboer ,  Pan Li ,  John Patrick Maxwell ,  Mark A. Morris ,  Albert Charles Pierce ,  Nathan D. Waal ,  Jinwang Xu

IPC: A61K31/506 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D239/42 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D491/056 ,  C07D495/04 ,  C07D521/00 ,  A61K41/00 ,  C07D417/10 ,  A61K9/20 ,  A61K9/48 ,  A61K31/5377 ,  A61K47/55 ,  A61K47/54 ,  A61K31/53

Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

公开(公告)号：US20190255062A1

公开(公告)日：2019-08-22

申请号：US16282083

申请日：2019-02-21

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： John Patrick Maxwell ,  Paul S. Charifson ,  Qing Tang ,  Steven M. Ronkin ,  Katrina Lee Jackson ,  Albert Charles Pierce ,  David J. Lauffer ,  Pan Li ,  Simon Giroux ,  Jinwang Xu ,  Kevin Michael Cottrell ,  Mark A. Morris ,  Nathan D. Waal ,  John J. Court ,  Wenxin Gu ,  Hongbo Deng

IPC: A61K31/5377 ,  C07D403/12 ,  C07D241/42 ,  A61K31/506 ,  C07D513/04 ,  C07D498/08 ,  C07D491/048 ,  C07D487/04 ,  C07D475/00 ,  C07D473/40 ,  C07D471/04 ,  C07D417/12 ,  C07D413/12 ,  C07D405/14 ,  C07D405/12 ,  C07D403/14 ,  C07D401/14 ,  C07D241/40 ,  C07D491/08 ,  C07D271/12 ,  C07D401/12 ,  C07D413/14 ,  C07D491/056 ,  C07D491/052 ,  C07D241/44 ,  C07D413/04 ,  A61K31/5386

Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

公开(公告)号：US09908878B2

公开(公告)日：2018-03-06

申请号：US15177546

申请日：2016-06-09

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  Michael J. Boyd ,  Ioana Davies ,  Hongbo Deng ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Joseph M. Kennedy ,  Brian Ledford ,  Mark W. Ledeboer ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang

IPC: C07D471/04 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6561 ,  A61K31/215 ,  A61K31/351 ,  A61K31/444 ,  A61K31/497

CPC classification number: C07D471/04 ,  A61K31/215 ,  A61K31/351 ,  A61K31/444 ,  A61K31/497 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6561

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

公开(公告)号：US09808459B2

公开(公告)日：2017-11-07

申请号：US15299757

申请日：2016-10-21

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  John J. Court ,  Hongbo Deng ,  Ioana Davies ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Dylan H. Jacobs ,  Joseph M. Kennedy ,  Mark W. Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang ,  M. Woods Wannamaker ,  Randal Byrn ,  Yi Zhou ,  Chao Lin ,  Min Jiang ,  Steven Jones ,  Ursula A. Germann ,  Francesco G. Salituro ,  Ann Dak-Yee Kwong

IPC: C07D401/04 ,  A61K31/506

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D239/30 ,  C07D401/04 ,  C07D401/10 ,  C07D471/04

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

公开(公告)号：US09345708B2

公开(公告)日：2016-05-24

申请号：US14305393

申请日：2014-06-16

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  John J. Court ,  Hongbo Deng ,  Ioana Davies ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Dylan H. Jacobs ,  Joseph M. Kennedy ,  Mark W. Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang ,  M. Woods Wannamaker ,  Randal Byrn ,  Yi Zhou ,  Chao Lin ,  Min Jiang ,  Steven Jones ,  Ursula A. Germann ,  Francesco G. Salituro ,  Ann Dak-Yee Kwong

IPC: A61K31/4965 ,  C07D401/00 ,  A61K31/5377 ,  A61K31/506 ,  C07D471/04 ,  C07D401/10 ,  A61K31/55 ,  A61K31/553 ,  C07D239/30 ,  C07D401/04

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D239/30 ,  C07D401/04 ,  C07D401/10 ,  C07D471/04

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract translation: 抑制生物样品或患者中流感病毒复制，减少生物样品或患者中的流感病毒数量和治疗患者流感的方法包括向所述生物样本或患者施用有效量的 由结构式（I）表示的化合物或其药学上可接受的盐，其中结构式（IA）的值如本文所述。 化合物由结构式（IA）或其药学上可接受的盐表示，其中结构式（IA）的值如本文所述。 药物组合物包含有效量的这种化合物或其药学上可接受的盐，以及药学上可接受的载体，佐剂或媒介物。

公开(公告)号：US20150191468A1

公开(公告)日：2015-07-09

申请号：US14666567

申请日：2015-03-24

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  Micheal J. Boyd ,  Ioana Davies ,  Hongbo Deng ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Joseph M. Kennedy ,  Brian Ledford ,  Mark W. Ledeboer ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang

IPC: C07D471/04 ,  C07F9/6561 ,  A61K45/06 ,  A61K31/506

CPC classification number: C07D471/04 ,  A61K31/215 ,  A61K31/351 ,  A61K31/444 ,  A61K31/497 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6561

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract translation: 抑制生物样品或患者中流感病毒复制，减少生物样品或患者中的流感病毒数量和治疗患者流感的方法包括向所述生物样本或患者施用有效量的 由结构式（I）表示的化合物：或其药学上可接受的盐，其中结构式（I）的值如本文所述。 化合物由结构式（I）表示或其药学上可接受的盐，其中结构式（I）的值如本文所述。 药物组合物包含有效量的这种化合物或其药学上可接受的盐，以及药学上可接受的载体，佐剂或媒介物。

公开(公告)号：US20140094473A1

公开(公告)日：2014-04-03

申请号：US14099054

申请日：2013-12-06

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  Michael J. Boyd ,  Ioana Davies ,  Hongbo Deng ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Joseph M. Kennedy ,  Brian Ledford ,  Mark W. Ledeboer ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/215 ,  A61K31/351 ,  A61K31/444 ,  A61K31/497 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6561

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract translation: 抑制生物样品或患者中流感病毒复制，减少生物样品或患者中的流感病毒数量和治疗患者流感的方法包括向所述生物样本或患者施用有效量的 由结构式（I）表示的化合物或其药学上可接受的盐，其中结构式（I）的值如本文所述。 化合物由结构式（I）表示或其药学上可接受的盐，其中结构式（I）的值如本文所述。 药物组合物包含有效量的这种化合物或其药学上可接受的盐，以及药学上可接受的载体，佐剂或媒介物。

公开(公告)号：US12195453B2

公开(公告)日：2025-01-14

申请号：US17930352

申请日：2022-09-07

Applicant: Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

Inventor： Henry Yu ,  Michael Clark ,  Guy Bemis ,  Michael Boyd ,  Kishan Chandupatla ,  Philip Collier ,  Hongbo Deng ,  Huijun Dong ,  Warren Dorsch ,  Russell R. Hoover ,  Mac Arthur Johnson, Jr. ,  Shashank Kulkarni ,  Marina Penney ,  Steven Ronkin ,  Darin Takemoto ,  Qing Tang ,  Nathan D. Waal ,  Tiansheng Wang ,  David J. Lauffer ,  Pan Li

IPC: C07D413/04 ,  A61K31/506 ,  A61K31/553 ,  A61P35/00 ,  C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D417/14 ,  C07D491/107 ,  C07D491/113

Abstract: The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).